Literature DB >> 28038891

Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.

Konstantinos Lazaridis1, Vassiliki Baltatzidi2, Nikolaos Trakas2, Eleni Koutroumpi2, Nikolaos Karandreas3, Socrates J Tzartos4.   

Abstract

Myasthenia gravis (MG) is usually caused by antibodies against the muscle acetylcholine receptor (AChR). Experimental autoimmune MG (EAMG) is the animal model of MG, typically induced by immunization of rodents with AChR isolated from the electric organ of Torpedo californica. We have successfully induced EAMG in Lewis rats by immunization with the extracellular domains (ECDs) of the human AChR subunits (α, β, γ, δ and ε) expressed in yeast. Analysis of the antibody titers revealed a robust antigenic response against all the peptides, but a marked difference in their pathogenicity; the α subunit ECD was the most pathogenic, resulting in the highest percentage of affected animals. Measurements of antibody titers, electromyographic tests and quantitation of the muscle AChR content, offered further support to these findings. The EAMG models presented herein, could be used for studying subunit-specific pathogenic mechanisms, and, more importantly, as tools for the evaluation of antigen-specific therapeutic approaches, which rely on the human AChR.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor; Animal model; Experimental autoimmune myasthenia gravis; Extracellular domain

Mesh:

Substances:

Year:  2016        PMID: 28038891     DOI: 10.1016/j.jneuroim.2016.12.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.

Authors:  Alessandra Consonni; Sapna Sharma; Karin Schön; Cristina Lebrero-Fernández; Elena Rinaldi; Nils Yngve Lycke; Fulvio Baggi
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

2.  Analysis of nAChR Autoantibodies Against Extracellular Epitopes in MG Patients.

Authors:  Maria Michail; Vasiliki Zouvelou; Maria Belimezi; Anna Haroniti; Marios Zouridakis; Paraskevi Zisimopoulou
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.003

3.  A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis.

Authors:  Konstantinos Lazaridis; Maria Fernandez-Santoscoy; Vasiliki Baltatzidou; Jan-Olof Andersson; Richard Christison; John Grünberg; Socrates Tzartos; Björn Löwenadler; Charlotte Fribert
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

4.  Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.

Authors:  Natalie Rose; Sebastian Holdermann; Nicholas S R Sanderson; Tobias Derfuss; Ilaria Callegari; Hyein Kim; Isabelle Fruh; Ludwig Kappos; Jens Kuhle; Matthias Müller
Journal:  Acta Neuropathol       Date:  2022-09-08       Impact factor: 15.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.